Figure 7.

KLRG1⁺ CD8⁺ T cell subsets from combination treated mice have enhanced proliferation and IFNγ production. C57BL/6 wild-type (WT) mice were challenged with 1 × 10⁵ Eμ-myc 4242 tumor cells and given combination treatment commencing on day 6 (n=4 per group), or left untreated. Splenic preparations from treated and untreated mice were subject to immunofluorescence staining and cytofluorimetric analysis. (A) Representative flow cytometry histograms of intracellular interferon γ (IFNγ) levels in the different activated CD8⁺ T-cell subsets (gated from total CD44⁺ cells) and naive CD8⁺ T cells (CD44^-) isolated from the spleen of a combination treated tumor-bearing mouse at day 19. (B) The percentage of each CD8⁺ T cell subset producing IFNγ (left graph) and mean fluorescent intensity (MFI) of IFNγ expression on IFNγ⁺ cells (right graph) from the spleens of untreated or combination treated mice at day 19 post-tumor inoculation. (C) The percentage of CD8⁺ T-cell subsets that produced IFNγ and incorporated BrdU in vivo. Data in B and C show means ± SEM; *P < 0.05; **P < 0.01; ***P < 0.001; ns = not significant, unpaired t-test.